Payment overview · 2025
General Payments
$3,453.93
57 reported records · 20 companies
Healthcare provider profile · identity verified
Jun Xu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1497010391
Verified facts
What the public records show
CMS Open Payments records show Jun Xu, M.D. received $3,453.93 in general payments during 2025 across 57 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $745.30 | 21.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $479.24 | 13.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $373.32 | 10.8% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $316.30 | 9.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $260.17 | 7.5% | 9 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $125.00 | 3.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $125.00 | 3.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 3.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.83 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $121.83 | 3.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $120.73 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $120.63 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.04 | 2.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.86 | 1.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $48.97 | 1.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.71 | 1.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.12 | 0.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.01 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.89 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,453.93 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $345.33 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $316.30 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $272.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $246.85 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $222.20 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $148.62 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $127.77 | 5 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $120.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $120.63 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $118.16 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.29 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.04 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $58.86 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $48.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.15 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 94 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 385 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 96 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 231 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
231 | 52 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
100 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
210 | 32 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
385 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
385 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1742 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 1351 | 208 |
| Losartan Potassium | Losartan Potassium | 1017 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 689 | 117 |
| Metformin Hcl | Metformin Hcl | 548 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 486 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 466 | 80 |
| Donepezil Hcl | Donepezil Hcl | 437 | 62 |
| Vascepa | Icosapent Ethyl | 435 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 404 | 94 |
| Clopidogrel | Clopidogrel Bisulfate | 390 | 60 |
| Eliquis | Apixaban | 385 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 64 |
| Gabapentin | Gabapentin | 372 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 333 | 92 |
| Omeprazole | Omeprazole | 311 | 69 |
| Famotidine | Famotidine | 299 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 50 |
| Xarelto | Rivaroxaban | 291 | 33 |
| Montelukast Sodium | Montelukast Sodium | 289 | 49 |
| Alendronate Sodium | Alendronate Sodium | 280 | 48 |
| Azithromycin | Azithromycin | 240 | 166 |
| Icosapent Ethyl | Icosapent Ethyl | 236 | 51 |
| Linzess | Linaclotide | 231 | 52 |
| Finasteride | Finasteride | 226 | 39 |
| Memantine Hcl | Memantine Hcl | 225 | 33 |
| Furosemide | Furosemide | 217 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 215 | 29 |
| Farxiga | Dapagliflozin Propanediol | 210 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 210 | 87 |
| Celecoxib | Celecoxib | 193 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 193 | 33 |
| Ezetimibe | Ezetimibe | 186 | 37 |
| Carvedilol | Carvedilol | 185 | 37 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 179 | 27 |
| Azelastine Hcl | Azelastine Hcl | 175 | 41 |
| Glimepiride | Glimepiride | 166 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 156 | 26 |
| Januvia | Sitagliptin Phosphate | 154 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 40 |
| Tradjenta | Linagliptin | 145 | 15 |
| Lorazepam | Lorazepam | 141 | 29 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 136 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 18 |
| Lactulose | Lactulose | 127 | 41 |
| Simvastatin | Simvastatin | 127 | 21 |
| Cyclosporine | Cyclosporine | 125 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 25 |
| Jardiance | Empagliflozin | 122 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 121 | 19 |
| Mirtazapine | Mirtazapine | 121 | 21 |
| Myrbetriq | Mirabegron | 121 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 20 |
| Levetiracetam | Levetiracetam | 116 | 15 |
| Lisinopril | Lisinopril | 116 | 15 |
| Baclofen | Baclofen | 108 | 23 |
| Meloxicam | Meloxicam | 106 | 24 |
| Trazodone Hcl | Trazodone Hcl | 104 | 23 |
| Bethanechol Chloride | Bethanechol Chloride | 102 | 22 |
| Allopurinol | Allopurinol | 100 | 21 |
| Prolia | Denosumab | 100 | 66 |
| Nifedipine Er | Nifedipine | 98 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 16 |
| Kerendia | Finerenone | 96 | 15 |
| Tramadol Hcl | Tramadol Hcl | 95 | 24 |
| Creon | Lipase/Protease/Amylase | 94 | 24 |
| Divalproex Sodium | Divalproex Sodium | 93 | 12 |
| Folic Acid | Folic Acid | 92 | 41 |
| Potassium Chloride | Potassium Chloride | 92 | 27 |
| Atenolol | Atenolol | 91 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 31 |
| Nitroglycerin | Nitroglycerin | 90 | 61 |
| Dapagliflozin | Dapagliflozin Propanediol | 88 | 20 |
| Terazosin Hcl | Terazosin Hcl | 86 | suppressed |
| Ranolazine Er | Ranolazine | 85 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 84 | 15 |
| Sertraline Hcl | Sertraline Hcl | 84 | 14 |
| Memantine Hcl Er | Memantine Hcl | 80 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 78 | suppressed |
| Restasis | Cyclosporine | 78 | 25 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 77 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 19 |
| Valsartan | Valsartan | 76 | 13 |
| Amoxicillin | Amoxicillin | 74 | 52 |
| Entresto | Sacubitril/Valsartan | 74 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 13 |
| Gemtesa | Vibegron | 72 | 11 |
| Dutasteride | Dutasteride | 68 | suppressed |
| Calcitriol | Calcitriol | 66 | suppressed |
| Alprazolam | Alprazolam | 65 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | suppressed |
| Acarbose | Acarbose | 64 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 63 | 28 |
| Hydrocortisone | Hydrocortisone | 62 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 12 |
| Lidocaine | Lidocaine | 59 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 12 |
| Digoxin | Digoxin | 58 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 56 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 55 | 17 |
| Midodrine Hcl | Midodrine Hcl | 55 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 55 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 23 |
| Temazepam | Temazepam | 53 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 48 | 11 |
| Cephalexin | Cephalexin | 47 | 41 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Telmisartan | Telmisartan | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 18 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 33 |
| Diclofenac Epolamine | Diclofenac Epolamine | 38 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 15 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 36 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Lacosamide | Lacosamide | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Brilinta | Ticagrelor | 30 | suppressed |
| Constulose | Lactulose | 30 | 12 |
| Fluocinonide | Fluocinonide | 30 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 12 |
| Levalbuterol Hcl | Levalbuterol Hcl | 30 | suppressed |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Procto-Med Hc | Hydrocortisone | 25 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Ofloxacin | Ofloxacin | 24 | 19 |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 24 | 12 |
| Ztlido | Lidocaine | 24 | suppressed |
| Bicalutamide | Bicalutamide | 23 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 23 | suppressed |
| Nateglinide | Nateglinide | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Ciclopirox | Ciclopirox | 22 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 12 |
| Ramelteon | Ramelteon | 18 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | 14 |
| Metronidazole | Metronidazole | 16 | 13 |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Neupro | Rotigotine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,453.93 · 57 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, CREON, ELIQUIS, EVENITY, FARXIGA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LINZESS, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, REZDIFFRA, XIFAXAN, Yorvipath, ZENPEP, ZERBAXA, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error